Olwill Shane 4
4 · PIERIS PHARMACEUTICALS, INC. · Filed Sep 1, 2021
Insider Transaction Report
Form 4
Olwill Shane
Chief Development Officer
Transactions
- Exercise/Conversion
Common Stock
2021-08-30$1.52/sh+38,400$58,368→ 43,038 total - Exercise/Conversion
Stock Option (right to buy)
2021-08-30−38,400→ 61,600 totalExercise: $1.52Exp: 2026-02-12→ Common Stock (100,000 underlying) - Sale
Common Stock
2021-08-30$5.00/sh−9,200$46,000→ 33,838 total - Sale
Common Stock
2021-08-30$5.15/sh−29,200$150,380→ 4,638 total
Footnotes (2)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.07 to $5.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
- [F2]The option has fully vested.